Bartomeu Massuti
@bmassutis
Followers
3K
Following
25K
Statuses
23K
Born in Majorca. Medical oncologist. Clinical researcher. Focused in lung cancer. World citizen. Major concerns: human inequality and blue planet environment
Alicante University Hospital
Joined September 2009
RT @gecp_org: 🙌Ayer entregamos en Madrid las becas de #investigacion👩⚕️🧑⚕️ GECP-Johnson&Johnson, apoyando proyectos innovadores en #cance…
0
3
0
1
1
2
RT @gecp_org: 👉 En torno al 10% de los cánceres de pulmón se diagnostican en menores de 40 años. 🧬 Según @bmassutis , secretario del GECP,…
0
5
0
RT @gecp_org: 🙌🏻Nueva edición del Curso de Competencias GECP🙌 Se celebrará del ⭕️ 20 al 21 de marzo de 2025 en el Parador de Alcalá de Hen…
0
2
0
New Targeted Therapy for Lung cáncer @OncoAlert Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | New England Journal of Medicine
1
15
25
On #WorldCancerDay remember that research are the key for improvement patient’s outcomes . Here you can see Facts and Figures of cancer in Spain by @_SEOM @OncoAlert
0
10
24
RT @OncoAlert: "Cancer is a word...NOT a sentence" #WorldCancerDay2025 United by Unique We are ALL 🌐 @OncoAlert
0
24
0
RT @gecp_org: ⭕Hoy, #DiaMundialContraElCancer, el presidente del GECP, el @MARIANOPROVENCI habla para @OncobitesTv sobre la evolución del d…
0
5
0
El cáncer se adelanta: alimentos procesados, retraso en la maternidad y contaminación explican el aumento de casos en jóvenes @gecp_org @GVAsalualicante a través de @diariomallorca
0
3
9
Ready for joining 👇👇👇
Day Two #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 @GlopesMd 🇺🇸 of @SylvesterCancer Covering Early #NSCLC 🫁 Non Small Cell #LungCancer in Review REGISTER NOW for a Live chat with Dr. Lopes In 2024, significant advancements in the treatment of early non-small cell lung cancer (NSCLC) emerged, particularly in targeted therapies and immunotherapy. New data have provided insights into the benefits of combining immunotherapy with chemotherapy in both neoadjuvant and adjuvant settings, with the first evidence of improved overall survival (OS) in these strategies. Alectinib has been established as the standard adjuvant treatment in the US and several other countries for patients with ALK-positive NSCLC. Additionally, the use of osimertinib has expanded to include consolidation therapy after chemoradiation in locally advanced (LA) disease, further enhancing treatment outcomes. Lung @ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @s_couraud @peters_solange @UmbertoMalapel1 @CharuAggarwalMD @christine_lovly @BairdAM @barlesi @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @JordiRemon @DrJNaidoo @Latinamd @JulienMazieres @TerriConneran
#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @Dr_Ivanoncologo @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
0
2
7
RT @StephenVLiu: Ten-year trends in well-being among oncology fellows reported @JCOOP_ASCO show some improvements since 2013. Burnout repor…
0
5
0
EMA starts the process for access to subcutaneous Amivantamab probably the only feasible way to wide its use in clinical practice CHMP recommends subcutaneous RYBREVANT®▼ for the treatment of advanced EGFR-mutated NSCLC @OncoAlert
0
10
14
RT @oncology_bg: Now Online! CSO RCT Checklist. @csoncol RCT team has just published in @TheLancetOncol a CHECKLIST to design and report c…
0
50
0
RT @StephenVLiu: Report from @ASCO on US oncologist well-being show 59% of oncologists report burnout and 75% of them plan on decreasing cl…
0
52
0
Impressive talk and task by @PrelajArsela at #ITCD2025 about IA potential in Oncoloy and Lung Cancer.and developingApollo 11 Project
1
10
24
RT @StephenVLiu: Dr. @peters_solange at #ITCD2025 gives a masterful talk on the next generation of checkpoint inhibitors and how novel agen…
0
20
0
RT @FCCPulmon: Great and diverse participation in the first discussion panel of the afternoon, moderated by @bmassutis and @javierDcastro.…
0
7
0